• Police seek suspects in deadly birthday party shooting
  • Lawmakers launch inquires into U.S. boat strike
  • Nov. 29, 2025, 10:07 PM EST / Updated Nov. 30, 2025,…
  • Mark Kelly says troops ‘can tell’ what orders…

Be that!

contact@bethat.ne.com

 

Be That ! Menu   ≡ ╳
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics Politics
☰

Be that!

Savewith a NBCUniversal ProfileCreate your free profile or log in to save this articleOct. 5, 2025, 8:48 AM EDTBy Megan Lebowitz and Alexandra MarquezWASHINGTON — Secretary of State Marco Rubio said in a Sunday interview on “Meet the Press” that ongoing negotiations between Hamas and Israel are not yet the end of the war and that setting up a group to govern Gaza “takes some time,” but emphasized that there was a plan to do so. It comes as Israel and Hamas appear to be inching closer to implementing a 20-point peace plan proposed by President Donald Trump. “Everyone has agreed, including Israel, that eventually, at some point here, as this process plays out, Gaza will be governed by a Palestinian technocratic group that’s not Hamas, that are not terrorists, with the help and the assistance and the guidance of an international consortium like the board of peace,” Rubio said, echoing the language of the proposed peace plan. At the same time, Rubio noted that “you can’t set up a governance structure in Gaza that’s not Hamas in three days.””I mean, it takes some time,” he said.The peace plan stipulates that Gaza would “be governed under the temporary transitional governance of a technocratic, apolitical Palestinian committee.” The plan also provides that Hamas, which had governed Gaza, would not have any role in governing in the future. Israeli Prime Minister Benjamin Netanyahu publicly backed the peace plan, which includes the release of all Israeli hostages by Hamas, during a visit to the White House last week.Hamas has expressed willingness to release all hostages, alive or dead, and plans to send a team on Sunday to Cairo, where more in-depth negotiations are slated to begin on Monday. Trump administration special envoy Steve Witkoff and the president’s son-in-law, Jared Kushner, plan to attend on behalf of the U.S.Palestinians mourn the death of loved ones killed in Israeli strikes, outside al-Aqsa Martyrs hospital in Deir el-Balah in the central Gaza Strip on Oct. 1. Bashar Taleb / AFP – Getty ImagesAsked by moderator Kristen Welker whether the peace negotiations mark the end of the war in Gaza, Rubio said “not yet.””There’s some work that remains to be done,” he said, pointing to ongoing meetings to determine the logistics of implementing a peace plan. The parties now need to determine first, how hostages are released, and second, how to create new Palestinian leadership. Palestinians watch smoke billowing during Israeli strikes at the Gaza Strip on Oct. 1,. Bashar Taleb / AFP – Getty Images”How do you create this Palestinian technocratic leadership that’s not Hamas, that’s not terrorists, and with the help of the international community?” Rubio said, laying out ongoing issues. “How do you disarm any sort of terrorist groups that are going to be building tunnels and conducting attacks against Israel?”There are ongoing talks to determine logistically how hostages could be released, he said. “You have to make sure the Red Cross can get there, what time they’re going to be there, where they’re going to be,” Rubio said. “All that has to be worked through.”Asked whether hostages could be released as early as this week, Rubio said, “We want it to be as soon as possible.”Megan LebowitzMegan Lebowitz is a politics reporter for NBC News.Alexandra MarquezAlexandra Marquez is a politics reporter for NBC News.

admin - Latest News - October 5, 2025
admin
28 views 12 secs 0 Comments




Secretary of State Marco Rubio said that ongoing negotiations between Hamas and Israel are not yet the end of the war



Source link

TAGS:
PREVIOUS
Savewith a NBCUniversal ProfileCreate your free profile or log in to save this articleOct. 5, 2025, 8:28 AM EDTBy Dennis Romero”Saturday Night Live” returned after its 50th anniversary season by mocking President Donald Trump’s administration and also making a little fun of itself. Puerto Rican musical sensation Bad Bunny returned to hosting duties amid conservative outcry at his selection as the 2026 Super Bowl halftime show performer.The cold open took viewers to Trump and Secretary of War Pete Hegseth’s meeting Tuesday with senior military officers from across the globe at the Marine Corps Base in Quantico, Virginia.Hegseth, played by “Weekend Update” co-host Colin Jost, was introduced by a colleague saying, “You will now be yelled at by a former Fox News host.”Jost’s Hegseth criticized the nation’s military branches for being out of shape. “Our military will now have the same rules as any good frat party: No fat chicks. And if you’re a fat dude, goddamn it you better be funny as hell,” he said.Trump, reprised by James Austin Johnson, said he showed up to the sketch to supervise the show.”I’m just here keeping my eye on ‘SNL,’ making sure they don’t say anything too mean about me,” he said, a seeming reference to Jimmy Kimmel’s briefly being taken off the air.Noting last season’s 50th anniversary celebrations, Johnson’s Trump said, “They should have called it at 50, right? So sad to see something get old and confused, and yet still demand your constant attention.”The 51st season, he said, was “off to a rough start.””Seventeen new cast members and they got the ‘Update’ guy doing the cold open,” Trump said.The night’s host, Bad Bunny, addressed the controversy over his scheduled performance at the 2026 Super Bowl.”I’m very happy and I think everyone is happy about it, even Fox News,” he said during the show’s opening monologue. The line was followed by a quick cut of Fox News hosts and commentators each saying one word that, in a sentence, stated, “He should be the next president.”Bad Bunny’s scheduled halftime performance has drawn the attention of U.S. Immigration and Customs Enforcement. He is a U.S. citizen. Some right-wing commentators have criticized the NFL’s halftime curation by noting Bad Bunny performs predominantly in Spanish, the country’s second most-spoken language.The performer, who recently wrapped up a residency in Puerto Rico, chose not to include U.S. locations for this concert tour this year, explaining in September that he feared they would draw immigration agents.Secretary of Homeland Security Kristi Noem said Friday on a podcast that ICE agents would be “all over” the Super Bowl, scheduled for Feb. 8 in Santa Clara, California.During the monologue, Bad Bunny included some words in Spanish on his choice as halftime performer, words he dedicated to “all the Latinos and Latinas in the entire world and here in the United States.””More than being an accomplishment of mine, it’s an accomplishment for everybody, demonstrating that our mark and our contribution to this country will never be able to be removed or erased by anybody,” he said in Spanish.He added, in English, “If you didn’t understand what I just said, you have four months to learn.”Bad Bunny’s hosting duties Saturday marked a milestone for the show. He helped “SNL” wrap its 50th season by appearing as its musical guest, and NBC said it was the first time an artist had been billed on the last show of a full season and the first show of the next.NBC said Bad Bunny first appeared on “SNL” in a Kenan Thompson sketch about baseball legend David Ortiz in 2020 before performing music on the show the next year.The artist also connected with global K-pop fans. A sketch about friends catching up at a restaurant after years apart featured a surprise cameo from some of the singing stars of “KPop Demon Hunters,” the hit animated Netflix movie about a K-Pop group who are undercover demon hunters. They performed part of their song “Golden,” which has topped Billboard charts for 11 weeks.“It’s actually not for kids,” he says of the trio. “It’s for smart adults.””SNL” had big shoes to fill after that 50th season, which included an anniversary special, a docuseries on the show’s history and a look back at its musical guests throughout the years.For Season 51, “SNL” welcomed five new performers with comedic or improvisational comedy background: Tommy Brennan, Jeremy Culhane, Kam Patterson, Veronika Slowikowska, and Ben Marshall, an “SNL” writer for three seasons and member of comedy group Please Don’t Destroy.Several cast members did not return for the new season, including Ego Nwodim, Heidi Gardner, Devon Walker, Michael Longfellow and Emil Wakim.Doja Cat made her debut as an “SNL” musical guest. The show also featured Hollywood heavy-hitters Jon Hamm and Benicio del Toro.Hamm (or, as Bad Bunny put it, “Juan Jamón”) showed up as a Bad Bunny fan and later as Profesor Jirafales in a parody of the classic Mexican comedy series “El Chavo del Ocho.”Del Toro made a cameo in a sketch set in 900 A.D. about the origins of Spanish, asking, “What if we made it harder to learn?”He also suggested the letter “R” should last “a long time,” and said, “I think we should take a nap in the middle of the day.”“SNL” airs on NBC, a division of NBCUniversal, which is also the parent company of NBC News.Dennis RomeroDennis Romero is a breaking news reporter for NBC News Digital.
NEXT
Judge Temporarily Blocks Trump From Sending Troops to Portland
Related Post
October 24, 2025
U.S. imposes sanctions against Russian oil
October 22, 2025
Driver arrested after car hits Secret Service property
November 26, 2025
Nov. 26, 2025, 5:00 AM ESTBy Maya Huter and Chloe MelasHawkins, Indiana, the fictional town in Netflix’s “Stranger Things,” is as central to the show’s plot as any of its main characters. Fans are so fascinated by the place that they travel from all over the world to experience it for themselves. Only, it’s not in Indiana — it’s in central Georgia, in the town of Jackson, about an hour south of Atlanta.The quaint town of 5,000 is in a wooded area just outside of Indian Springs, one of Georgia’s oldest state parks. Locals say the town was once marked by significant drug activity and was desperate for business. “It was a bootstrap situation,” said Hannah Thompson, who owns a local shop dedicated to 1980s memorabilia and runs daily “Stranger Tours” with her husband, Cameron. “If you’re looking around, you’re seeing empty shops, many of those were empty for almost a decade.”
October 1, 2025
Oct. 1, 2025, 5:00 AM EDTBy Abigail Brooks and Zinhle EssamuahWESTWEGO, Louisiana — Robin Phillip’s fresh haircut is dyed her favorite color — green. But beneath the dye job is a scar that runs along the side of her head, the result of two craniotomies. For years, Phillip, 45, suffered from what she thought were migraines. It wasn’t until early 2018, when she had to leave her warehouse shift to drive to the hospital, that she learned her headaches were a symptom of something more serious. She said she nearly crashed on the drive to the emergency room, blinded by pain. “The nurse said, ‘OK, what’s your pain from 1 to 10?’ I said 11, 12,” said Phillip. “They put me in the chair, and I don’t remember nothing after that.”Phillip awoke later to shocking news: She had an intracranial meningioma — a tumor of the lining of the brain. She needed emergency surgery.After the procedure, Phillip lost vision in her left eye and had to re-learn how to walk. Unable to work, she lost her apartment and moved in with her mother until she could get back on her feet. Robin Phillip during a radiation session in 2024. A mask holds her head in place for the treatment.Courtesy Robin Phillip“I was feeling lost, because where would I have possibly gotten a tumor from? I had a regular life. I did regular things,” she said. “What could have possibly caused this to happen to me?”Today, Phillip believes her birth control is to blame. For nearly 30 years, stopping only when she had her two children, she used Depo-Provera — a progestin shot given three times a year. She’s one of more than 1,000 women suing Pfizer, which makes the drug, alleging the company knew more about the risks and failed to warn users. Pfizer has moved to have the suit dismissed, arguing the case is pre-empted by a Food and Drug Administration decision, and says it stands behind the safety and efficacy of Depo-Provera.According to the Centers for Disease Control and Prevention, 1 in 4 sexually active women in the United States have used Depo-Provera. Black women use it at nearly double the national rate. Meningiomas are usually not cancerous — meaning they don’t spread to other parts of the body — but they can be harmful depending on their size and where they grow. Phillip’s tumor was pressing on her optic nerve, causing vision problems.Recent researchIn recent years, several studies have shown a possible link between Depo-Provera use and an increased risk of developing meningioma. One of them, published earlier this month in JAMA Neurology, linked medroxyprogesterone acetate (MPA), the drug in Depo-Provera, with a twofold increase in risk for meningioma. The risk was greatest in women who used the contraceptive for more than four years or started after age 31.Another one, a 2024 study published in the The BMJ based on French data, found a fivefold increase in risk for meningioma for long-term Depo-Provera users. Doctors caution that the studies are observational, meaning they cannot prove the medication caused the tumors. Dr. David Raleigh, a radiation oncologist who specializes in brain tumors and who is the chair of meningioma research at the University of California San Francisco’s Department of Radiation Oncology, said that female sex hormones — progesterone in particular — are linked to meningioma. (Progestin, the hormone in Depo-Provera, is a synthetic version of progesterone.) Meningiomas are the only brain tumors that are more common in women than in men, he added.Still, Raleigh said this doesn’t necessarily mean that progesterone is causing a meningioma to form. “All the available data suggest that progesterone is fuel on the fire,” he said. “Progesterone didn’t necessarily start the fire, but the available data suggest that it’s like dumping gas on it.” He said that the recent studies linking Depo-Provera to meningioma give him pause.“Those of us in the business often recommend that patients with meningioma avoid hormone replacement therapy, use nonhormone based means of contraception, if possible, and to be cautious with pregnancy and fertility planning because of these very well documented associations,” he said. “These new studies only amplify those concerns and considerations.”The overall risk of developing meningioma remains small: About 39,000 meningiomas are diagnosed each year in the U.S.“Overall, meningioma is not common. This is not a type of tumor that we see very often,” said Dr. Colleen Denny, an OB-GYN at NYU Langone Health. “The likelihood of having a meningioma as a Depo user is incredibly low. It’s just that it’s incredibly, incredibly low for people who don’t use Depo.”The American College of Obstetricians and Gynecologists (ACOG) published a response to The BMJ study urging caution, saying that, “according to the study, five out of 10,000 women using medroxyprogesterone acetate may possibly develop meningioma compared to one out of 10,000 women not using the medication.”“The risk that they’re finding is incredibly small,” said Dr. Nisha Verma, senior adviser for reproductive health policy for advocacy at ACOG. “I think it is a consideration we can talk to patients about, among all of the considerations that patients go through.”“Uterine cancer is a lot more common than meningioma, and Depo reduces your risk of uterine cancer. So how do you balance that?” Denny said. “It’s complex, and it often depends on the individual patients.”Phillip says even that small risk would have been too much for her.“If I would have [known] from the get-go, I would have never took that shot,” she said. The lawsuitPhillip is now one of more than 1,000 women suing Pfizer, the maker of Depo-Provera, alleging that the company failed to warn them about the risk. “These women all have meningiomas. Many have surgery, some have radiation, and they’ve all had their lives greatly impacted,” said Ellen Relkin, a lawyer representing Phillip and some of the other plaintiffs. Phillip’s lawsuit points to several studies dating as far back as 1983 showing a link between progesterone and meningioma. The lawsuit says those studies created an “unassignable duty to investigate,” and that Pfizer should have studied the risks associated with Depo-Provera sooner. Phillip needed two surgeries to remove a meningioma. A scar from the operations runs down the side of her head.NBC News“Defendants willfully, wantonly, and intentionally conspired, and acted in concert, to ignore relevant safety concerns and to deliberately not study the long-term safety and efficacy of Depo-Provera, particularly in chronic long-term users of Depo-Provera,” the complaint says. Verma, of ACOG, said that hormonal birth control is well-studied before it hits the market.“Birth control methods that are commercially available have been studied extensively before becoming available to the public, and so we’ve studied every type of birth control. We’ve looked at safety measures,” she said. “We have guidelines that do intensive reviews of all of the data and help us support patients in what methods may be safer for them.”In a statement to NBC News, Pfizer said it stands behind the “safety and efficacy of Depo-Provera.” In a court filing earlier this month, the company asked a judge to dismiss the case, saying that it became aware of the risks of meningioma associated with Depo-Provera in 2023, and submitted an application to the Food and Drug Administration to add a warning to the drug’s label. The application also requested adding warnings to two pills containing much lower doses of MPA. The FDA denied that request, according to the filing.The FDA declined NBC News’ request for comment, but in its denial letter to Pfizer, which is included in company’s filing, it said: “The findings of the available observational studies alone do not support the addition of a warning on Meningioma risk to medroxyprogesterone acetate (MPA)-containing products.”A spokesperson for Pfizer told NBC News that because of the FDA’s denial, federal law pre-empts the company from changing the warning label on Depo-Provera.In an interview with NBC News, Phillips’ lawyer Relkin said Pfizer had enough information to study the possible risks associated with Depo-Provera on its own before 2023 and accused the company of making an “overbroad and half-baked” effort to warn patients by submitting an application to add a warning label to every medication containing MPA.“Depo-Provera is 150 milligrams. Three, four times a year, a very high dose,” Relkin said. “There are low-dose, 2.5 and 5 mg pills, where there’s no data showing that they cause a problem.”“The dose makes the poison,” she added. “By asking to change the label for all, they were inviting a rejection.”Pfizer denied that accusation in its court filing. “If FDA truly thought a meningioma warning was necessary for some products (and not others) … FDA could have ‘promptly’ communicated to Pfizer,” it wrote.Changes abroad Outside of the U.S., however, changes have been made to Pfizer’s label.The European Medicines Agency added meningioma as a “possible side effect” of drugs with high doses of medroxyprogesterone acetate in 2024, and Pfizer went on to communicate that risk to doctors in the European Union. Canada’s label for the drug, updated in 2024, includes meningioma in its “warnings and precautions” section, stating that “meningiomas have been reported following long-term administration of progestins, including medroxyprogesterone acetate.”In January, South Africa’s drug regulatory agency also recommended updating the drug label for MPA to include meningioma risk. Phillip’s lawsuit alleges that Pfizer knew of the potential risk years before those changes overseas were made, however, citing a 2006 Canadian drug label which lists meningioma as one of the “Post-Market Adverse Drug Reactions” — adverse events that are reported after a drug has already been approved. The 2006 label notes that “the nature of post-marketing surveillance makes it difficult to determine if a reported event was actually caused by DEPO-PROVERA.”“Just because something happened associated in time with something, it doesn’t mean that one thing caused the other,” said Dr. Janet Woodcock, a former FDA principal deputy commissioner. “It’s in a company’s best interest to put everything on there, because then if they’re sued, they’d say, ‘Well, it was in the fine print.’”Woodcock, who is not involved with the lawsuit, noted the FDA typically has the final word on drug labels.According to Pfizer’s court filings, the company resubmitted its application to the FDA in June 2025. Phillip, right, rings the bell on her last day of radiation treatment on March 25, 2024.Courtesy Robin Phillip“FDA has still not approved any meningioma warning, and Pfizer’s renewed request remains pending,” the filing said.Relkin said an earlier warning would have changed everything for Phillip and her other clients.After her surgery in 2018, Phillip continued to take Depo-Provera. Her doctors were unable to remove the entire tumor in 2018 and she needed a second surgery in 2022, followed by radiation treatment from 2022 to 2024.Even still, doctors weren’t able to remove the entire tumor because of how close it is to her optic nerve.Phillip says she continued taking Depo-Provera until she saw posts on social media in 2024 about the studies linking the drug to meningioma. Earlier this month, she had her first set of brain scans since going off the drug. She said her radiologist told her that the meningioma is shrinking. “My body is telling me, my head is telling me I don’t have that much pain like I used to have,” she said. Abigail BrooksAbigail Brooks is a producer for NBC News.Zinhle EssamuahZinhle Essamuah is a correspondent and anchor for NBC News.
Comments are closed.
Scroll To Top
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics
© Copyright 2025 - Be That ! . All Rights Reserved